Increased fucosylation and other carbohydrate changes in haptoglobin in ovarian cancer

Thompson, Stephen; Dargan, Everett L.; Turner, G. A.

doi:10.1016/0304-3835(92)90278-4

Cited by 84 publications

(49 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Investigations of ovarian cancer haptoglobins using digoxigenin-labelled lectins suggest that normal and ovarian cancer haptoglobins differ in their content of carbohydrate structures containing sialic acid-linked a(2-6) or a(2-3) to galactose and in the type of glycan branching (9). Turner's group (19)(20)(21)(22) has shown that ovarian cancer sera have high levels of an abnormal form of haptoglobin in which fucose occupies three positions (mainly a(l-3)) in carbohydrate chains. The fucose content of haptoglobin was elevated 7-fold in ovarian cancer.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Measurements of Haptoglobin by the Reaction with Concanavalin A in Sera of Patients with Ovarian Tumours

Kaţnik¹,

Jadach²,

Kmieciak³

et al. 1995

CCLM

View full text Add to dashboard Cite

Summary:The concentration of haptoglobin in sera of healthy women and patients with non-malignant and malignant ovarian tumours was measured by two methods, i.e. complex formation with haemoglobin and complex formation with concanavalin A. High correlation (r = 0.74) between both the methods was found in the group of healthy women, but correlation coefficients were much lower in the group of non-malignant and malignant tumours (r = 0.42 and 0.37, respectively). Direct determinations of haptoglobin, and calculation of the ratio of haptoglobin bound to concanavalin A to haptoglobin bound to haemoglobin revealed statistically significant differences among the examined groups. Comparison of two methods of haptoglobin quantitation suggest that processes connected with ovarian disorders may alter the glycosylation of haptoglobin oligosaccharide chains.

show abstract

Section: Resultsmentioning

confidence: 99%

“…In contrast, the high fucose content in haptoglobin from ovarian cancer patients is known to be branchingindependent (19,21).…”

Section: Hp-hbmentioning

confidence: 95%

Measurements of Haptoglobin by the Reaction with Concanavalin A in Sera of Patients with Ovarian Tumours

Kaţnik¹,

Jadach²,

Kmieciak³

et al. 1995

CCLM

View full text Add to dashboard Cite

show abstract

“…Haptoglobin level was shown to be affected by the amount of tumour burden and was not dependent on the histologic type or grade of ovarian malignancy (Mueller et al, 1971). Some studies have shown increased fucosylation and other carbohydrate changes in serum haptoglobin of ovarian cancer patients (Thompson et al, 1992b). Strong association between abnormally fucosylated haptoglobin and a 1,3 fucosyltransferase activity has been demonstrated in the blood specimens of ovarian cancer patients (Thompson et al, 1992a).…”

Section: Discussionmentioning

confidence: 99%

“…Recently, correlation between haptoglobin, CA 125 and interleukin-6 have been shown in ovarian cancer (Dobryszycka et al, 1999). As these studies relied on spectrophotometric (Mueller et al, 1971), immunodiffusion (Thompson et al, 1992b) and electrophoretic methods (Thompson et al, 1992a) for the detection of haptoglobin, it is not surprising that homologous native protein was detected rather than the precursor. Another recent study has shown haptoglobin a-subunit as potential serum biomarker in ovarian cancer (Ye et al, 2003).…”

Section: Discussionmentioning

confidence: 99%

Proteomic-based identification of haptoglobin-1 precursor as a novel circulating biomarker of ovarian cancer

et al. 2004

View full text Add to dashboard Cite

Screening for specific biomarkers of early-stage detection of ovarian cancer is a major health priority due to the asymptomatic nature and poor survival characteristic of the disease. We utilised two-dimensional gel electrophoresis (2DE) to identify differentially expressed proteins in the serum of ovarian cancer patients that may be useful as biomarkers of this disease. In this study, 38 ovarian cancer patients at different pathological grades (grade 1 (n ¼ 6), grade 2 (n ¼ 8) and grade 3 (n ¼ 24)) were compared to a control group of eight healthy women. Serum samples were treated with a mixture of Affigel-Blue and protein A (5 : 1) for 1 h to remove high abundance protein (e.g. immunoglobulin and albumin) and were displayed using 11 cm, pH 4 -7 isoelectric focusing strips for the first dimension and 10% acrylamide gel electrophoresis for the second dimension. Protein spots were visualised by SYPRO-Ruby staining, imaged by FX-imager and compared and analysed by PDQuest software. A total of 24 serum proteins were differentially expressed in grade 1 (Po0.05), 31 in grade 2 (Po0.05) and 25 in grade 3 (Po0.05) ovarian cancer patients. Six of the protein spots that were significantly upregulated in all groups of ovarian cancer patients were identified by nano-electrospray quadrupole quadrupole time-of-flight mass spectrometry (n-ESIQ(q)TOFMS) and matrix-assisted laser desorption ionisation time-of-flight mass spectrometry (MALDI-TOFMS) as isoforms of haptoglobin-1 precursor (HAP1), a liver glycoprotein present in human serum. Further identification of the spots at different pathological grades was confirmed by Western blotting using monoclonal antibody against a haptoglobin epitope contained within HAP1. Immunohistochemical localisation of HAP1-like activity was present in malignant ovarian epithelium and stroma but strong immunostaining was present in blood vessels, areas with myxomatous stroma and vascular spaces. No tissue localisation of HAP1-like immunoreactivity was observed in normal ovarian surface epithelium. These data highlight the need to assess circulating concentration of HAP1 in the serum of ovarian cancer patients and evaluate its potential as a biomarker in the early diagnosis of ovarian cancer.

show abstract

“…33−35 Several fucosylated proteins have already been found upregulated in ovarian cancer, which include alpha-1-antitrypsin, 36 haptoglobin, 37 and alpha-1-proteinase inhibitor. 38 In the present work, we have identified the fucosylation changes of CBG, HRG, and CFAB in the serum of ovarian cancer patients.…”

Section: Journal Of Proteome Researchmentioning

confidence: 99%

Markers of Ovarian Cancer Using a Glycoprotein/Antibody Array

Lubman¹,

Buckanovich²

2013

View full text Add to dashboard Cite

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.

show abstract

Increased fucosylation and other carbohydrate changes in haptoglobin in ovarian cancer

Cited by 84 publications

References 13 publications

Measurements of Haptoglobin by the Reaction with Concanavalin A in Sera of Patients with Ovarian Tumours

Measurements of Haptoglobin by the Reaction with Concanavalin A in Sera of Patients with Ovarian Tumours

Proteomic-based identification of haptoglobin-1 precursor as a novel circulating biomarker of ovarian cancer

Markers of Ovarian Cancer Using a Glycoprotein/Antibody Array

Contact Info

Product

Resources

About